FDA-cleared profile

Methinks CTA Stroke

Methinks Software S.L. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.

Clinical role
Triage and notification support
Images and patients
CT/CTA · Brain
Key limitation
Keep in mind: Preview is informational and not diagnostic; the device is not a replacement for full clinical evaluation, standard care, or physician interpretation.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain Input: Brain CT angiography in DICOM format from adults above 21 years with suspected acute stroke; the algorithm evaluates the terminal ICA, MCA-M1, and MCA-M2 territories.
  • Who uses it?Intended users: Trained physicians, including emergency physicians, neurologists, radiologists, neuroradiologists, neurovascular interventionists, and other trained stroke professionals
  • What does the software produce?Output: A suspected-LVO notification sent to PACS and/or notification clients for the neurovascular specialist; images may be previewed in an informational viewer, while notified clinicians must review non-compressed diagnostic images and the full patient context.
  • What is its most important limitation?Key limitation: Preview is informational and not diagnostic; the device is not a replacement for full clinical evaluation, standard care, or physician interpretation.

Clinical takeaway. Clinical role: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.

Evidence takeaway. Evidence from the reviewed source record: Retrospective blinded multicenter multinational validation used 336 CTA cases, including 110 LVO-positive and 226 LVO-negative cases from institutions distinct from training data.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.
  • Exact FDA submission
  • Checked 2026-09-06
Workflow role
Triage and notification support
  • Exact FDA submission
  • Checked 2026-09-06
Required input
Brain CT angiography in DICOM format from adults above 21 years with suspected acute stroke; the algorithm evaluates the terminal ICA, MCA-M1, and MCA-M2 territories.
  • Exact FDA submission
  • Checked 2026-09-06
Output and clinician action
A suspected-LVO notification sent to PACS and/or notification clients for the neurovascular specialist; images may be previewed in an informational viewer, while notified clinicians must review non-compressed diagnostic images and the full patient context.
  • Exact FDA submission
  • Checked 2026-09-06
Care setting
Adult acute-stroke hospital workflow; patients above 21 years with suspected acute stroke
  • Exact FDA submission
  • Checked 2026-09-06
Intended users
Trained physicians, including emergency physicians, neurologists, radiologists, neuroradiologists, neurovascular interventionists, and other trained stroke professionals
  • Exact FDA submission
  • Checked 2026-09-06
Limitations
Preview is informational and not diagnostic; the device is not a replacement for full clinical evaluation, standard care, or physician interpretation.
  • Exact FDA submission
  • Checked 2026-09-06
Evidence summary
Retrospective blinded multicenter multinational validation used 336 CTA cases, including 110 LVO-positive and 226 LVO-negative cases from institutions distinct from training data.
  • Exact FDA submission
  • Checked 2026-09-06

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Retrospective blinded multicenter multinational validation used 336 CTA cases, including 110 LVO-positive and 226 LVO-negative cases from institutions distinct from training data.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported sensitivity
98.2% (95% CI 93.6%-99.8%) for LVO detection in 336 cases.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported specificity
91.6% (95% CI 87.2%-94.9%) for LVO detection in 336 cases.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06

Sensitivity

98.2 percent

  • EndpointLVO detection
  • Population336 CTA cases; 110 LVO-positive and 226 LVO-negative
  • Tested versionMethinks CTA Stroke submitted in K251590; build not stated

Specificity

91.6 percent

  • EndpointLVO detection
  • Population336 CTA cases; 110 LVO-positive and 226 LVO-negative
  • Tested versionMethinks CTA Stroke submitted in K251590; build not stated

Mean time to notification

3.3 minutes

  • EndpointDICOM receipt through analysis and PACS/client notification
  • PopulationCTA cases in the FDA workflow timing evaluation
  • Tested versionMethinks CTA Stroke submitted in K251590; build not stated

Methinks CTA Stroke multicenter LVO validation

  • DesignRetrospective blinded multicenter multinational standalone performance study
  • Population336 CTA cases, including 110 LVO-positive and 226 LVO-negative cases from institutions distinct from training data
  • Scopeexact submission
  • Tested versionMethinks CTA Stroke submitted in K251590; build not stated
  • Samplen=336
  • IndependenceIndependence not established

K251590

The FDA describes cases from institutions distinct from training data; two U.S.-board-certified neuroradiologists interpreted cases with third-reader adjudication. Independence of investigators or sponsorship was not established.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Brain CT angiography in DICOM format from adults above 21 years with suspected acute stroke; the algorithm evaluates the terminal ICA, MCA-M1, and MCA-M2 territories.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-06 · FDA 510(k) K251590: Methinks CTA Stroke

  2. Routing

    Source context, not route validation: The submission describes DICOM ingestion, PACS delivery, and notification clients for parallel specialist notification; site-specific interfaces and routing rules require confirmation.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-06 · FDA 510(k) K251590: Methinks CTA Stroke

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed exact-submission material establishes PACS/notification workflow but not a current hosting model or regional data flow.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 ·

  4. Returned objects

    Source context, not route validation: A suspected-LVO notification sent to PACS and/or notification clients for the neurovascular specialist; images may be previewed in an informational viewer, while notified clinicians must review non-compressed diagnostic images and the full patient context.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-06 · FDA 510(k) K251590: Methinks CTA Stroke

  5. Viewer/worklist/report

    Unresolved route: A suspected-LVO notification sent to PACS and/or notification clients for the neurovascular specialist; images may be previewed in an informational viewer, while notified clinicians must review non-compressed diagnostic images and the full patient context.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-06 · FDA 510(k) K251590: Methinks CTA Stroke

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The submission describes DICOM ingestion, PACS delivery, and notification clients for parallel specialist notification; site-specific interfaces and routing rules require confirmation.
  • Exact FDA submission
  • Checked 2026-09-06
Security
The FDA submission describes a risk-based cybersecurity process including threat modeling, vulnerability assessment, third-party penetration testing, SBOM, authentication/authorization, logging, cryptography, monitoring, and recovery controls; current attestation, scope, and expiration were not established.
  • Exact FDA submission
  • Checked 2026-09-06

This records controls described in the submission, not a current independent security certification.

CTA-to-PACS notification

The exact submission describes DICOM CTA ingestion, LVO analysis in the terminal ICA/MCA-M1/MCA-M2, and notifications to PACS and/or specialist clients in parallel to standard care.

exact submission · checked 2026-09-06

Methinks family coordination workflow

Methinks' official platform page describes NCCT/CTA stroke workflows with AI alerts, team coordination, video communication, image viewing, and Microsoft Teams integration; the current configuration of K251590 requires confirmation.

product family · checked 2026-09-07
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K251590
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-08-20
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
26Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

No stored PubMed or ClinicalTrials.gov candidate identifiers for this submission in the 2026-09-01 snapshot; exact-submission recall candidate review was also zero. This metadata screen is not a full paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, literature index, trial registry, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission

    No public amount, range, currency, geography, or contract term was established.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Methinks Stroke reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Deployment: Not verified - checked 2026-09-07 - Exact FDA submission

    The reviewed exact-submission material establishes PACS/notification workflow but not a current hosting model or regional data flow.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-07 - Exact FDA submission

    Current onboarding, competency, and support commitments were not established.

  • Monitoring: Not verified - checked 2026-09-07 - Exact FDA submission

    Local acceptance testing, production monitoring, update control, and drift review were not established.

7 sources - 3 history items

Source ledger

  1. FDA 510(k) K251590: Methinks CTA Stroke

    U.S. Food and Drug Administration - Published 2025-08-20 - Accessed 2026-09-06

    Scope: identity, purpose, clinicalUse, modality, anatomy, input, output, limitations, integration, evidenceSummary, evidenceMetrics, evidenceStudies, security

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Methinks CTA Stroke model card (K251590)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Methinks official stroke platform page

    Methinks - Accessed 2026-09-07

    Scope: productFamilyWorkflow, implementationCapabilities

Research history

  1. K251590 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251151

Rapid CTA 360

iSchemaView

Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-07-16
FDA-cleared K250685

Methinks NCCT Stroke

Methinks Software S.L.

Authorized purpose: Methinks NCCT Stroke analyzes adult non-contrast head CT to flag suspected intracranial hemorrhage and suspected large-vessel occlusion of the ICA, MCA-M1, or MCA-M2 for parallel workflow triage via PACS and/or notifications; previews are informational, not diagnostic, and a negative notification does not rule out LVO or replace CTA/standard care.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-06-16
FDA-cleared K240353

Hyper Insight - ICH

SK Inc.

Authorized purpose: Notification-only triage for suspected acute intracranial hemorrhage on non-contrast brain CT, sharing cases with medical specialists in parallel with standard care.

Modality
CT/CTA
Anatomy
Brain
Decision
2024-07-01

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history